Demyelinating Events During Exposure To TNF-Inhibitors Compared To CsDMARDs In Patients With Rheumatoid Arthritis: Results From The French National Healthcare Database (ACR Convergence 2026) - Sep 8, 2026 - Abstract #807; Pres time: Nov 8, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Periods of exposure to TNFi (infliximab, etanercept, adalimumab, certolizumab pegol, golimumab, originator molecules, and biosimilars) and csDMARDs (methotrexate, leflunomide, sulfasalazine, and hydroxychloroquine) were defined with no lag period and with a 3-month carry-over period. Demyelination following DMARD treatment is rare in RA. However, this study found a significant increased risk of DemEv associated to TNFi exposure compared with csDMARDs. Figure 1: Weighted cumulative incidence of demyelinating events (DemEv) during exposure to TNFi and csDMARDs in patients with rheumatoid arthritis Figure 2: risk of demyelinating events (DemEv), of DemEv involving the central nervous system (CNS) or the peripheral nervous system (PNS) associated to TNFi compared with csDMARDs, in the whole study population, and according to age group at index date (results of the structural marginal Cox models are provided as hazard ratios [HR] with their 95% confidence intervals..."
Clinical • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
|
|
Joanna KEDRA1; Aya Ajrouche1; Yann De Rycke1; Octave Guinebretiere1; Julien Kirchgesner1; Elisabeth Maillart2; Florence Tubach1; Bruno Fautrel3
|